Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma
about
Effect of cyclosporine on blood pressureApproach to Patients with Severe Asthma: a Consensus Statement from the Respiratory Care Experts' Input Forum (RC-EIF), IranAsthma that is unresponsive to usual careDifficult asthma: beyond the guidelinesAlternative strategies in the treatment of bronchial asthma.Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: glucocorticoids and cyclosporine.Asthma--the changing face of drug therapy.Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.Eosinophil apoptosis--pathophysiologic and therapeutic implications.Novel therapy for asthma.Children with difficult asthma: a practical approach.Cyclosporin as an oral corticosteroid sparing agent in stable asthma.Novel drugs for treating asthma.Recommendation for optimal management of severe refractory asthma.Is Th1 the solution for Th2 in asthma?Differential effects of cyclosporine A after acute antigen challenge in sensitized cats in vivo and ex vivo.Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy.A new class of cyclosporin analogues for the treatment of asthma.Management of asthma in adults: current therapy and future directionsThe use of cyclosporin in corticosteroid dependent asthmaCRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patientsAsthma refractory to glucocorticoids: the role of newer immunosuppressants.Severe asthma in adults.Therapeutic options for severe asthmaA rational approach to the management of severe refractory asthma.Clinical and molecular aspects of glucocorticoid resistant asthmaRationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids.Anti-inflammatory effects of intranasal cyclosporine for allergic rhinitis in a mouse model.In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling.Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription.Human late asthmatic reactions.Evidence that cyclosporin A and dexamethasone inhibit allergic airway eosinophilic inflammation via suppression of interleukin-5 synthesis by T cells.Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils.Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics.Distinct leucocyte redistribution after glucocorticoid treatment among difficult-to-treat asthmatic patients.Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma.
P2860
Q24240463-56EFACE2-DA08-4667-99BE-D7C3614F7560Q26777154-B0672A89-E428-4C76-B420-B5EAE5C69087Q33575466-BAA8DFF6-D9AD-4AB5-8298-8DD0A9D875ABQ33634099-A37455E0-A203-4FA9-B043-375AF405B182Q33801225-92BD10AE-3860-4D31-979C-E4FAC79A54B7Q33807037-21AABA63-BAE1-4360-BFBD-3936180AD9BAQ33930453-3117C1D3-2017-41A3-AF80-AA286ABE9BBAQ33976334-60C6664C-3C13-4F52-8719-D6F9618DD10CQ34059300-24DED8F2-6437-43F4-9A60-4163A16C3FFFQ34074657-096D532B-D52F-4A55-884D-B545640A2EB1Q34273468-647F3A86-CB71-47DD-A805-B0AEA2E330BFQ34282007-18F4D0D9-C59F-4F29-91E7-1D01D27BBADBQ34567539-14D46A18-F515-4761-B661-0C29BEC90CA6Q34620187-5FF3861F-09B2-440A-8ABE-F769C2C3B277Q34632441-BDA1649B-F1D5-49FE-A90E-D60603EE1C1FQ35027344-584491F3-2950-429E-9EFA-95560AA1458CQ35044321-4AA60CFC-157F-4530-AA2D-1FAE5CA0C5CEQ35094688-5C087DDE-6C49-49E6-876B-EC9773DA9A90Q35143482-C2DC1C80-00BF-46D1-B7B3-EC89B003BBECQ35257675-7EADA489-C1C1-4FF5-90DA-25162553DCBBQ35457347-79DDFE59-FA2D-4C8D-ADCB-B3CA95A3A9ACQ35627919-0C3E44CF-B1A0-4DD9-867D-4F2EBD29147EQ36105312-C7A8A481-C2BF-4576-A28A-F9B10CF474B5Q36286252-25057B5B-FCDE-418C-AB3C-0BE2426651FAQ36334802-59E681FB-DCC7-4310-8FEA-01309D2AFCB9Q36645790-CDC05A15-3DF2-4D06-A09A-DC02EFDAF8BCQ37901553-8711CE69-86BB-4F3B-9C87-3D98E548DC17Q40469419-0BD6A2EF-7254-4384-8436-AE7903B514B8Q40693637-16F5A14B-54F8-4BCD-8376-CD2220BBEEE3Q41096837-A1FF2B05-CE51-4921-960D-8A33E449EED3Q41494401-129FD1A2-66B8-4460-809B-19E436B94B8EQ43184833-40334E6E-7E87-43C6-8220-154F690A9C85Q44340018-045DC0DA-7491-47AD-A4F4-4C29D591D462Q44863693-89F96B05-E461-4500-BA97-8E6093100FA9Q45245832-528F1161-7145-4AEB-A597-33CD9DCE360EQ45926675-FEA33C39-E2C3-41B8-99F5-80213C1BF84CQ50723376-8A01649F-5A9C-4666-B17B-E0F7DDB6FD3BQ54136937-2D80EB25-C136-4CB8-B932-8D6A65085329
P2860
Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma
description
im Februar 1996 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1996
@uk
name
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@en
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@nl
type
label
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@en
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@nl
prefLabel
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@en
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@nl
P2093
P1476
Double-blind, placebo-controll ...... orticosteroid-dependent asthma
@en
P2093
P304
P356
10.1164/AJRCCM.153.2.8564089
P407
P577
1996-02-01T00:00:00Z